

Versameb to present at the BIO Asia-Taiwan Conference

22 July 2022, Basel, Switzerland: Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Executive Officer, Klaas Zuideveld will be presenting on the Company’s mRNA engineering technology platform *VERSagile* and lead therapeutic candidate VMB-100 at the [BIO Asia-Taiwan Conference](#), taking place on 27-31 July 2022 in Taiwan.

The theme of the Conference is “Connecting the Asia Value Chain” and reflects the insights of the healthcare industry in the new era for innovation, supply, and investment, primarily focusing on Precision Medicine, Advanced Therapies, Digital Health, Investment and Collaboration, and Regional Partnerships with industry executives and investors from North America, Europe, and Asia to explore opportunities within Asia's emerging biotech sector.

Versameb has developed a groundbreaking, proprietary technology platform which optimizes the application of functional RNA in different disease contexts. Its lead therapeutic candidate VMB-100 has demonstrated first-in-class potential for treatment of Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter.

[BIO Asia-Taiwan Conference](#)

Date: 27-31 July 2022, Taiwan

Presentation by: Klaas Zuideveld

Session: “New Modalities to Cure”

Date & Time: 27 July, 16.00-16.15 Taipei time (10.00-10.15 CEST)

Klaas Zuideveld, Chief Executive Officer, said: “We are delighted to be presenting at the BIO Asia Taiwan Conference on our proprietary platform *VERSagile* amongst key industry executives and investors from North America, Europe and Asia, to demonstrate our commitment and focus as we continue to advance our pioneering next generation of RNA therapeutics to address the unmet medical needs of patients.”

If you would like to meet with the Versameb team at the above event, please contact us using the details provided below. For more information, please visit us at <https://versameb.com/upcoming-conferences-events/>

-Ends-

Contact for media enquiries:

Versameb

Dr Klaas Zuideveld, CEO

lr@versameb.com

Optimum Strategic Communications

Mary Clark, Charlotte Hepburne-Scott, Zoe Bolt



Tel: +44 (0)20 3882 9621

versameb@optimumcomms.com

About Versameb

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb's proprietary technology platform, *VERSagile*, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve. The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards the completion of a first in-human/proof-of-concept clinical study while advancing its platform. More information on Versameb can be found at www.versameb.com as well as on [LinkedIn](#).

About BIO Asia Taiwan

The event brings together biotechnology and pharmaceutical executives and investors from North America, Europe and Asia, to explore business opportunities within Taiwan's emerging biotech sector. The gathering will feature internationally renowned speakers, online company presentations from Asia and around the world, BIO One-on-One Partnering™ meetings, online seminars and workshops, and an online exhibition. Online meeting lounges and other social media-type activities will facilitate and replicate the social and networking elements so important to the typical conference experience. For more information, please visit www.bioasiataiwan.com